更新于：2024-05-16

Sulpiride

舒必利

更新于：2024-05-16

概要

概要

基本信息

药物类型

小分子化药

别名

(±)-sulpiride、5-(Aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxybenzamide、N-((1-Ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoylbenzamide

+ [13]

靶点

DRDs

作用机制

DRDs拮抗剂(多巴胺受体家族拮抗剂)

治疗领域

消化系统疾病其他疾病

在研适应症

抑郁症精神分裂症十二指肠溃疡+ [1]

非在研适应症-

原研机构

Nichi-Iko Pharmaceutical Co., Ltd.

在研机构

无锡济煜山禾药业股份有限公司

Nichi-Iko Pharmaceutical Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (1973-01-13),

十二指肠溃疡胃溃疡

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C15H23N3O4S

InChIKeyBGRJTUBHPOOWDU-UHFFFAOYSA-N

CAS号15676-16-1

关联

项与舒必利相关的临床试验

NCT05208294 / CompletedN/AIIT

The Role of Dopamine, Reward Learning and Prefrontal Activity in Expectation-induced Mood Enhancement

Although placebo effects on depressive symptoms are well documented, the underlying mechanisms and moderating factors of expectation effects on mood and depression are poorly understood. Various studies show reduced reward processing in clinical and subclinical depression, presumably due to abnormalities in the dopamine (DA) system. Here, the investigators will test whether expectation-induced mood enhancement is mediated by endogenous DA activity and reward learning, and moderated by individual differences in depression-related personality traits. Healthy participants (N=296) will be tested for potentially relevant personality traits and given an inactive substance (placebo) or a DA D2-receptor antagonist sulpiride (400 mg) in combination with a low vs. high expectation manipulation (fully crossed 2x2 placebo design) before performing a probabilistic reinforcement learning task, an effort expenditure task, and undergo a depressed mood induction procedure. Further, EEG indices will be assessed throughout the tasks.
The investigators expect that positive expectation improves participants' reinforcement learning, increases participants' willingness to make effort in order to obtain reward, and leads to less depressive symptoms as indicated by mood ratings upon depressive mood induction. If the overall effect of positive expectations is mediated by DA, high-dose sulpiride should block expectation-induced effects, i.e., the anticipated enhanced reinforcement learning and effort expenditure as well as mood improvement in the high vs. low expectation group.

开始日期2021-12-09

申办/合作机构

Philipps University Marburg Medical Center

NCT05884671 / CompletedN/A

Dopaminergic Mechanisms of Gating Working Memory, Learning and Motivation: a Pharmaco-fMRI Study

Rationale: To unravel the role of dopamine in gating of working memory, motivation and learning.
Objective: The primary objective of this study is to isolate effects of blocking D2 receptor stimulation on gating of working memory, reinforcement learning and reward-based motivation, and their associated physiological changes (measured with fMRI and eye tracking). The secondary objective is to assess the degree to which the effects of D2 receptor action vary as a function of proxy measures of baseline dopamine levels.
Study design: A double-blind placebo controlled within-subject design will be employed, in which young healthy participants are tested twice, once on placebo, and once on a low oral dose (400mg) of the D2 receptor antagonist sulpiride. This design and drug dose is commonly used in our lab without side effects (previously approved CMO protocols 2011/204, 2008/078 & 2016/2646).
Study population: Healthy human participants, 18 - 45 yr old. We will recruit 46 participants.
Intervention: Participants will receive both 400 mg sulpiride and placebo, in separate sessions in a counterbalanced order.
Main study parameters/endpoints: BOLD signal measured with fMRI, and behavioural performance on cognitive tasks.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will attend 3 study sessions: A screening session and 2 pharmaco-fMRI sessions (sulpiride and placebo). Participants will complete a baseline battery of tasks and questionnaires, a structural MRI scan, as well as a battery of tasks both in and outside the scanner. On the day preceding each pharmaco-fMRI session, participants will have to adhere to some simple restrictions with respect to medication, alcohol and drug intake. On the day of testing participants will have to refrain from smoking and stimulant-containing drinks. Sulpiride can be administered safely without any relevant risk of serious adverse events and has been approved for clinical use in the Netherlands.

开始日期2021-09-23

申办/合作机构

F.C. Donders Centre for Cognitive Neuroimaging

NCT04583111 / Unknown status临床4期

The Effect of Antiemetics on Bowel Preparation Before Colonoscopy

Polyethylene glycol (PEG) is one of the most common laxatives used in colonoscopy. However, 5 - 15% of patients can not complete the preparation due to its poor taste and large volume. So this study is aimed to explore the effect of antiemetics on abdominal discomforts associated with PEG.

开始日期2020-03-01

申办/合作机构

上海仁玑医院管理有限公司

100 项与舒必利相关的临床结果

登录后查看更多信息

100 项与舒必利相关的转化医学

登录后查看更多信息

100 项与舒必利相关的专利（医药）

登录后查看更多信息

4,840

项与舒必利相关的文献（医药）

2024-07-01·Brain Research

1-(Phenylselanyl)-2-(p-tolyl)indolizine: A selenoindolizine with potential antidepressant-like activity in mice mediated by the modulation of dopaminergic and noradrenergic systems

Article

作者: Brüning, César Augusto ; Penteado, Filipe ; Lenardão, Eder João ; Dapper, Luiz Henrique ; Besckow, Evelyn Mianes ; Pires, Camila Simões ; Zuge, Narryman Pinto ; Nunes, Gustavo D'Avila ; Bortolatto, Cristiani Folharini ; Presa, Marcelo Heinemann ; Gomes, Caroline Signorini ; da Rocha, Marcia Juciele

1-(Phenylselanyl)-2-(p-tolyl)indolizine (MeSeI) is a selenoindolizine with an antidepressant-like effect in mice by regulation of the serotonergic system. This study investigated the involvement of dopaminergic and noradrenergic systems in the antidepressant-like action of MeSeI. For this purpose, Swiss male mice were pretreated with different antagonists, after 15 min, the MeSeI was administrated by intragastric (i.g.) via; after 30 min, the mouse behavior was assessed in the forced swimming test (FST). The action of MeSeI on the activity of monoamine oxidase (MAO) was determined. The pretreatment of mice with haloperidol (0.05 mg/kg, intraperitoneally, i.p.; non-selective dopamine receptor antagonist), sulpiride (50 mg/kg, i.p.; D₂ receptor antagonist), yohimbine (1 mg/kg, i.p.; α₂ receptor antagonist), and propranolol (2 mg/kg, i.p.; non-selective β receptor antagonist), inhibited the anti-immobility action of MeSeI (50 mg/kg, i.g.) in the FST. This blocking effect was not observed when SCH23390 (0.01 mg/kg, i.p.; D₁ receptor antagonist), and prazosin (1 mg/kg, i.p.; α₁ receptor antagonist) were administered. The coadministration of subeffective doses of bupropion (3 mg/kg. i.g.; dopamine and noradrenaline reuptake inhibitor) and MeSeI (0.5 mg/kg. i.g.) reduced the immobility time in the FST. Furthermore, MeSeI inhibited MAO-A and B activities in vitro and ex vivo tests. These results suggest that MeSeI exerts its antidepressant-like effect via regulation of the D₂, α₂, and β₁ receptors and the inhibition of MAO-A and B activities. Molecular docking investigations corroborated these results. This study provides comprehensive insights into the antidepressant-like mechanism of MeSeI in mice, suggesting its potential as a novel antidepressant candidate.

2024-05-01·Biomedicine & Pharmacotherapy

Conjugation of sulpiride with a cell penetrating peptide to augment the antidepressant efficacy and reduce serum prolactin levels

Article

作者: Chen, Haotian ; Yan, Zelong ; Huang, Ruiyan ; Yang, Yu ; Ning, Jiangyue ; Ding, Li ; Liang, Yuan ; Bao, Xingyan ; Shu, Chang

Depression ranks as the fourth most prevalent global disease, with suicide incidents occurring at a younger age. Sulpiride (SUL), an atypical antidepressant drug acting as a dopamine D2 receptor antagonist and possessing anti-inflammatory properties, exhibits limited ability to penetrate the blood brain barrier (BBB). This weak penetration hampers its inhibitory effect on prolactin release in the pituitary gland, consequently leading to hyperprolactinemia. In order to enhance the central nervous system efficacy of sulpiride and reduce serum prolactin levels, we covalently linked sulpiride to VPALR derived from the nuclear DNA repair protein ku70. In vivo study on depressive mice using intraperitoneal injection of VPALR-SUL demonstrated a significant increase in struggle time and total distance compared to those treated with only sulpiride while also reducing serum prolactin concentration. The pharmacokinetic study results showed that VPALR-SUL prolonged half-life and increased bioavailability. In conclusion, VPALR-SUL exhibited potential for enhancing sulpiride transport across the BBB, augmenting its antidepressant effects, and reducing serum prolactin levels. This study laid a foundation for improving sulpiride delivery and developing novel antidepressants.

2024-05-01·Neuropharmacology

Sex differences in risk-based decision-making and the modulation of risk preference by dopamine-2 like receptors in rats

Article

作者: Ayoub, Samantha M ; Libster, Avraham M ; Young, Jared W ; Barnes, Samuel A ; Dulawa, Stephanie C

Heightened risk-based decision-making is observed across several neuropsychiatric disorders including schizophrenia, bipolar disorder, and Parkinson's disease, yet no treatments exist that effectively normalize this aberrant behavior. Preclinical risk-based decision-making paradigms have identified the important modulatory roles of dopamine and sex in the performance of such tasks, though specific task parameters may alter such effects (e.g., punishment and reward values). Previous work has highlighted the role of dopamine 2-like receptors (D2R) during performance of the Risk Preference Task (RPT) in male rats, however sex was not considered as a factor in this study, nor were treatments identified that reduced risk preference. Here, we utilized the RPT to determine sex-dependent differences in baseline performance and impact of the D2R receptor agonist pramipexole (PPX), and antagonist sulpiride (SUL) on behavioral performance. Female rats exhibited heightened risk-preference during baseline testing. Consistent with human studies, PPX increased risk-preference across sex, though the effects of PPX were more pronounced in female animals. Importantly, SUL reduced risk-preference in these rats across sexes. Thus, under the task specifications of the RPT that does not include punishment, female rats were more risk-preferring and required higher PPX doses to promote risky choices compared to males. Furthermore, blockade of D2R receptors may reduce risk-preference of rats, though further studies are required.

项与舒必利相关的新闻（医药）

2024-03-27

·米内网

【市场】6亿大品种！天士力过评了

精彩内容3月26日，NMPA官网显示，天士力全资子公司天士力帝益的尼可地尔片通过仿制药一致性评价，为国内第3家过评。尼可地尔片为抗心绞痛药物，2022年在中国公立医疗机构终端销售额超过6亿元。尼可地尔片用于治疗心绞痛，为国家医保甲类品种，该药具有三重作用靶点，不仅作用于冠状动脉，还作用于微血管和心肌线粒体。米内网数据显示，近年来尼可地尔片市场呈现持续攀升态势，2022年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售额突破6亿元，同比增长46.89%，持续实现双位数增长。中国公立医疗机构终端尼可地尔片销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局国内已有50家企业获得尼可地尔片的国产批文，但目前该产品仅有西安汉丰药业、山西鑫煜制药、天士力帝益3家企业通过仿制药一致性评价。天士力帝益过评品种来源：米内网一致性评价进度数据库截至目前，天士力帝益已有17个品种通过/视同通过一致性评价。其中，赖诺普利氢氯噻嗪片、右佐匹克隆片、替莫唑胺胶囊、苯扎贝特缓释片、米诺膦酸片、舒必利片、盐酸苯海索片等7个品种为国内首家过评。资料来源：米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价

2024-03-05

·CPHI制药在线

新药 | 创新药再遭FDA拒批，抗精神病药这一蓝海赛道还有哪些故事可讲？

关注并星标CPHI制药在线近日，精神分裂症领域再传坏消息。致力于精神药物研发的Minerva Neurosciences公司宣布，FDA就其Roluperidone药物用于治疗精神分裂症阴性症状的新药申请（NDA）发出了完整回复函（CRL）。 Roluperidone是一款5-羟色胺2A（5-HT2A）受体和σ2受体拮抗剂，其旨在避免直接阻断多巴胺能受体（第一代和第二代抗精神病药的关键药理学靶点），同时保持对5-HT2A 的特定亚型血清素受体（第二代抗精神病药的另一个关键靶点）以及其他药理学靶点（σ2和肾上腺素能-α1A）的阻断，用于治疗精神分裂症患者阴性症状。 Roluperidone最初由Mitsubishi Tanabe公司开发。2007年8月，Minerva Neurosciences与Mitsubishi Tanabe达成许可协议，获得roluperidone在除中国、日本、印度和韩国等亚洲国家以外地区的独家开发和商业化权益。 Roluperidone一波三折，终折戟事实上，早在2022年8月22日，Minerva就向FDA提交了roluperidone的NDA。2022年10月，Minerva收到了FDA的CRL。同时FDA表示，Minerva可以进行type A会议讨论CRL的内容。不过在2022年11月30日举行的type A会议之后，FDA仍拒绝批准roluperidone。 Minerva并未就此放弃。2023年5月，Minerva宣布FDA再次接收了roluperidone用于治疗精神分裂症患者阴性症状的NDA资料。 Roluperidone的上市申请主要基于两项III期临床试验（MIN-101C03和MIN-101C07）的积极结果。MIN-101C03共纳入515例患者，旨在评估roluperidone两种剂量（32mg和64mg）治疗精神分裂症的中度至重度阴性症状和稳定阳性症状的患者的疗效和安全性。MIN-101C07研究是MIN-101C03的扩展研究，共纳入333例患者，主要终点为第40周时Marder阴性症状因素评分（NSFS）的变化。 MIN-101C03结果显示，在第12周，roluperidone组患者的NSFS评分改善显著优于安慰剂组。MIN-101C07结果显示，第40周时，在改良意向性治疗人群中，roluperidone组患者的NSFS评分改善（p≤0.044）和个人和社会表现（PSP）总分改善（p≤0.017）均显著优于安慰剂组。此次NDA申请仍以失败告终。在FDA回复的CRL中，提到了四点拒批原因：1.MIN-101C03研究达到了主要疗效终点，但仅凭此不足以充分证明roluperidone的有效性；2.NDA材料未提供入组患者所服用的其它抗精神病药物的信息；3.NDA材料缺乏证明roluperidone对改善精神分裂症阴性症状具有临床意义的必要数据；4.在已提交的安全性数据中，至少服用12个月拟议剂量（64mg）roluperidone的患者数量不足。从CRL的内容可知，roluperidone要想获批上市，还有很多工作要做。百亿蓝海赛道，治疗选择有限精神分裂症是一种慢性、严重且使人衰弱的精神疾病，其特征是思维、感知、情绪、语言、自我意识和行为的扭曲，该疾病影响着全世界2000多万人。在医学领域，精神分裂症主要分为阳性和阴性症状。其中阳性症状是指正常功能行为的夸大或歪曲，主要表现有幻觉、妄想、思维障碍、反复离奇的行为动作等，也是精神分裂症致残的主因。阴性症状主要表现包括情感冷漠、社交疏离、动机与快感丧失、消极厌世等抑郁样特征。总体来看，阴性症状患者占比更高，首发精神分裂症患者中，大约50-90%是阴性。不过，阴性和阳性划分并不绝对。因为随着病情的进展，大约有20-40%阴性症状为主的患者也会出现阳性症状（即明显症状）；而经过治疗后，阳性为主的患者也可能转化为阴性症状为主的患者。由于精神分裂症主要发生在青壮年人群中，而且易反复发作，需长期服药，给社会和家庭造成了沉重负担。调研机构Expert Market Research数据显示，2023年，全球精神分裂症药物的市场价值为81.8亿美元。预计到2032年，市场价值将达到129.7亿美元。与巨大的市场形成鲜明对比的是，抗精神分裂症药物的稀缺。目前，抗精神病药是治疗精神分裂症的首选，大致分为两大类：第一代抗精神病药（典型抗精神病药物）和第二代抗精神病药（非典型抗精神病药物）。第一代抗精神病药大多是特异性多巴胺2型（D2）受体拮抗剂，代表药物包括氯丙嗪、奋乃静、氟哌啶醇及其长效剂、舒必利等，该机制类药物效果有限且耐受性较差。第二代抗精神病药具有多靶点的药理学特征，对D2受体具有拮抗或部分激动功能，同时阻断5-HT2A受体，代表药物为利培酮、帕利哌酮、奥氮平等，占据市场主导地位。无论是第一代抗精神病药还是第二代，均对阴性症状的治疗效果有限，而且还会出现糖脂代谢紊乱、引起体重变化等不良反应。准确地说，即使经过数十年发展，目前仍无针对精神分裂症阴性症状的疗法。其他抗精分新药研究近况 ►KarXT KarXT是KarunaTherapeutics开发的一种口服创新复方制剂——毒蕈碱型受体（M受体）激活剂Xanomeline+M受体拮抗剂Trospium，旨在以优先刺激中枢神经系统的M受体，同时避免刺激周围神经组织M受体来改善精神病症状。 Xanomeline是由诺和诺德原研的高选择性M1受体激动剂，20 世纪90年代授权于礼来用于精神分裂症和阿尔茨海默病临床开发。由于该药物会对周围神经产生不良副作用，最终礼来放弃了这一项目。2018年，Karuna重启了Xanomeline开发，并与已获FDA批准上市的毒蕈碱受体拮抗剂Trospium组成复方制剂。去年12月14日，Karuna公布了KarXT的III期EMERGENT-2临床结果。研究显示，治疗第5周时，与安慰剂组相比，KarXT组精神分裂症患者的阳性症状（如幻觉、妄想）和阴性症状（如冷漠，认知障碍）量表（PANSS）评分显示出统计学意义和临床意义的减少（( KarXT -21.2 vs 安慰剂 -11.6），且总体耐受性良好。目前，Karuna已向FDA申请KarXT的NDA。如果KarXT获得批准，它将是50多年來第一个被批准用于治疗精神分裂症的新药类别。 ►Ulotaront（SEP-363856） Ulotaront（SEP-363856）是住友制药/大冢制药共同研发的一款微量胺相关受体1（TAAR1）和5-HT1A受体双重激动剂。其中TAAR是一种G蛋白偶联受体，不仅可以被微量胺激活，也可以被多巴胺或血清素等单胺类物质激活。研究显示，部分精神分裂症患者存在TAAR1基因变异。去年8月，住友制药/大冢制药宣布，Ulotaront治疗急性精神分裂症的两项III期DIAMOND 1和DIAMOND 2研究未达到主要研究终点。其中DIAMOND 1研究旨在急性精神分裂症成人患者中评估ulotaront(50mg/天和75mg/天)与安慰剂的疗效、安全性和耐受性，共纳入435例受试者。DIAMOND 2研究旨在急性精神分裂症成人患者中评估ulotaront (75mg/d和100mg/d)与安慰剂的疗效、安全性和耐受性，为期6周，共纳入464例受试者。 ►Pimavanserin Pimavanserin是Acadiaia研发的一款选择性5-HT反向激动剂和拮抗剂，优先靶向5-HT2A受体，于2016年4月获批，是首款治疗与帕金森病精神病（PDP）相关的幻觉和妄想的药物。目前，Acadiaia正在进行pimavanserin治疗精神分裂症的相关临床试验。聚焦国内，由于抗精神分裂症新药研发难度大，国内药企对该领域布局较少，主要以仿制药为主。如海正药业、豪森药业、正大天晴和丽珠集团等10家企业布局了盐酸鲁拉西酮（用于治疗成人精神分裂症）片仿制药；康弘药业、恩华药业、华海药业、上药中西制药等近20家企业布局了阿立哌唑仿制药。研发抗精神病新药或创新剂型的国内药企主要有绿叶制药、再鼎医药、丽珠集团。由于抗精神分裂症药领域还有很大的发挥空间，期待更多国内药企入场布局。参考来源： 1.https://www.biospace.com/article/releases/karuna-therapeutics-announces-the-lancet-publication-of-data-from-phase-3-emergent-2-trial-evaluating-karxt-in-schizophrenia/. 2.The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch. 3.https://www.biospace.com/article/releases/karuna-therapeutics-announces-the-lancet-publication-of-data-from-phase-3-emergent-2-trial-evaluating-karxt-in-schizophrenia/.【智药研习社近期直播预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

临床3期临床成功申请上市

2023-12-13

·米内网

【关注】大三甲引进23款新药，济川、华东、复星……

精彩内容12月12日，成都市第四人民医院发布公告称，将公开引进23款新药以满足院内用药需求。其中，不乏丙戊酸钠注射剂、利拉鲁肽注射剂等2022年在中国公立医疗机构终端销售额超10亿元的重磅药，和对乙酰氨基酚注射剂、舒必利注射剂等销售增速达四位数及以上的潜力品种，涉及济川药业、华东医药、复星医药等知名药企。来源：成都市第四人民医院官网按治疗大类统计，此次成都市第四人民医院公开引进的药物以神经系统药物为主，占据10个席位；抗肿瘤和免疫调节剂、呼吸系统用药分别占3个和2个；血液和造血系统药物、心脑血管系统药物、消化系统及代谢药、肌肉-骨骼系统、神经系统疾病用药等八大类别药物均各占1个。公开引进新药名单来源：成都市第四人民医院，米内网整理其中，丙戊酸钠注射剂适用于曾经服用过丙戊酸钠口服剂型并获得满意疗效，但暂时无法继续服用该口服剂型的癫痫患者。2022年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端该药销售额接近15亿元。米内网数据显示，丙戊酸钠注射剂已上市的产品有注射用丙戊酸钠和丙戊酸钠注射用浓溶液。丙戊酸钠注射剂为第八批国采品种，倍特药业、汇宇制药、福安药业等8家企业成功中标，而济川药业、青峰医药等企业有望凭借“光脚”中标优势，进一步扩大其产品市场规模。丙戊酸钠注射用浓溶液第八批国采中标企业来源：米内网中国上市药品（MID）数据库利拉鲁肽注射剂是一款人胰高血糖素样肽-1（GLP-1）受体激动剂，与人GLP-1具有97%的序列同源性，兼具减肥、降糖和心血管获益的功效。据诺和诺德季报和米内网数据显示，利拉鲁肽注射剂在2023年前三季度全球销售额约为22亿美元，而在2022年中国公立医疗机构终端销售额超过16亿元。近年来中国公立医疗机构终端利拉鲁肽注射剂销售趋势（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局米内网数据显示，利拉鲁肽注射剂已有2家国产企业拥有生产批文，包括华东医药（2023年3月获批）、通化东宝药业（2023年11月获批）；正大天晴药业和珠海联邦生物分别以新药3.3类报产在审；成都圣诺生物、深圳翰宇药业、深圳健翔生物均以仿制4类提交上市申请，目前已获批临床。资料来源：米内网数据库、成都市第四人民医院官网注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至12月13日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准免疫疗法医药出海

100 项与舒必利相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01226	舒必利	N05AL01	DB00391

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
抑郁症	日本	Nichi-Iko Pharmaceutical Co., Ltd.	1979-08-03
精神分裂症	日本	Nichi-Iko Pharmaceutical Co., Ltd.	1979-08-03
十二指肠溃疡	日本	Nichi-Iko Pharmaceutical Co., Ltd.	1973-01-13
胃溃疡	日本	Nichi-Iko Pharmaceutical Co., Ltd.	1973-01-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00280501 (ARVO2007)	N/A	dopamine	19	Quetiapine	鏇選憲築獵積鬱襯襯範(糧鹽鬱簾積襯餘範蓋鹹) = 顧襯觸網願糧觸鑰構獵餘築艱遞憲簾餘餘餘蓋 (廠製構鹽鑰觸範積鏇製 )	积极	2007-05-01
				Sulpiride	鏇選憲築獵積鬱襯襯範(糧鹽鬱簾積襯餘範蓋鹹) = 構鏇廠夢選憲淵憲餘醖餘築艱遞憲簾餘餘餘蓋 (廠製構鹽鑰觸範積鏇製 )
MDS2020	N/A	消化性溃疡 \| 帕金森障碍 \| 胃食管反流	-	Sulpiride-treated group	遞積憲襯廠廠製醖壓築(獵襯網遞醖製積蓋願遞) = 範餘簾製選壓衊選窪窪壓壓餘糧簾憲蓋淵餘膚 (選觸齋顧艱醖鏇製窪廠 )	-	2020-09-12
				Sulpiride	遞積憲襯廠廠製醖壓築(獵襯網遞醖製積蓋願遞) = 蓋鏇觸簾憲鬱遞鬱醖製壓壓餘糧簾憲蓋淵餘膚 (選觸齋顧艱醖鏇製窪廠 )
ARVO2020	N/A	糖尿病性视网膜病变 prolactin	-	Sulpiride	(選糧餘範壓憲願製淵願) = reduced diabetes-induced retinal vasopermeability 鹹鹽壓醖積衊襯構獵齋 (壓製糧膚鹽願繭簾齋鹽 )	-	2020-06-01
				Sulpiride
Pubmed \| Psychopharmacology (Berl)	N/A	精神分裂症维持	-	Chlorpromazine	(餘醖網觸簾蓋選淵窪憲) = Anticholinergic side effects were most common with clozapine and chlorpromazine 壓憲艱鑰齋遞鑰餘積鏇 (構鏇鬱窪糧鑰築遞製構 ) 更多	-	2011-08-01
				Sulpiride